Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives $62.17 Average Price Target from Brokerages

Posted by on Jul 10th, 2026

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Get Free Report) have been assigned an average rating of “Hold” from the seven analysts that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $62.8333.

A number of analysts have recently weighed in on the company. Wall Street Zen raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 4th. Cantor Fitzgerald upped their price target on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a report on Thursday. Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, June 24th. Finally, Zacks Research raised shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th.

Check Out Our Latest Stock Analysis on SUPN

Institutional Trading of Supernus Pharmaceuticals

Several large investors have recently modified their holdings of SUPN. Rubric Capital Management LP purchased a new position in Supernus Pharmaceuticals during the 2nd quarter valued at about $21,908,000. Assenagon Asset Management S.A. bought a new stake in shares of Supernus Pharmaceuticals in the 1st quarter worth approximately $27,428,000. Woodline Partners LP increased its stake in shares of Supernus Pharmaceuticals by 63.5% during the third quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock valued at $60,398,000 after buying an additional 490,835 shares during the period. SG Americas Securities LLC increased its stake in shares of Supernus Pharmaceuticals by 2,847.0% during the first quarter. SG Americas Securities LLC now owns 377,213 shares of the specialty pharmaceutical company’s stock valued at $19,498,000 after buying an additional 364,413 shares during the period. Finally, Bank of America Corp DE raised its holdings in shares of Supernus Pharmaceuticals by 67.1% during the third quarter. Bank of America Corp DE now owns 842,890 shares of the specialty pharmaceutical company’s stock valued at $40,282,000 after acquiring an additional 338,584 shares in the last quarter.

Supernus Pharmaceuticals Trading Down 3.4%

SUPN opened at $48.75 on Friday. The business’s 50-day moving average price is $47.10 and its 200-day moving average price is $49.50. Supernus Pharmaceuticals has a 12 month low of $32.20 and a 12 month high of $59.68. The company has a market cap of $2.83 billion, a P/E ratio of -95.59, a P/E/G ratio of 1.08 and a beta of 0.54.

About Supernus Pharmaceuticals

(Get Free Report)

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.

Featured Articles

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.